

Help Acknowledge Rare Disease Day by Sharing the XLHED Network.



A Commitment to Advancing Research in 2011 and Beyond

In honor of Rare Disease Day February 28, 2011, we're asking you to join us, along with other individuals and family members affected by XLHED, in the *Share the Spirit* initiative. You can help by e-mailing affected friends, family members, and medical professionals with the **XLHED Network link**, or sharing it with friends or newsgroups on Facebook on February 28. *Share the Spirit* is an opportunity for you to make an impact on this special day. The more people get involved, the better equipped we are as a community to advance potential treatment options.

In 2011, Edimer continues to focus on improving the health and quality of life of those affected by XLHED and to developing EDI200, an investigational therapeutic protein. We are studying whether EDI200 may be a substitute for a protein involved in the formation of sweat glands, teeth, hair, and certain glandular structures that is missing in patients with XLHED. EDI200 is the first investigational therapy ever developed to potentially treat XLHED in the newborn population, and we anticipate launching clinical trials in 2012. We made significant strides this past year, and we are pleased to share with you some recent highlights:

- **XLHED Network** — Last year we celebrated the launch of the XLHED Network. The Network reflects our commitment to keeping you and your family informed about the latest news and resources. You can help us grow the Network by sharing this link with family members and healthcare providers: www.XLHEDnetwork.com.
- **Research Grant Awarded** — Three months ago we were awarded a grant from the Qualifying Therapeutic Discovery Project program. This acknowledgement marks a major milestone for Edimer. The grant will enable us to invest in additional research as we move the EDI200 program forward.
- **Clinical Research Results Presented** — At the 60th Annual Meeting of the American Society of Human Genetics in November, we announced key findings of a study exploring novel approaches to the assessment of sweat function in males with XLHED. The data confirmed a defect in sweat gland function as a disease indicator in patients with XLHED, even in the setting of normal sweat pore counts. This information contributes to our understanding of XLHED and to how we approach the development of potential treatment options. **Click here** to learn more.
- **EDI200** — Last October we presented an update on EDI200 at the International Ectodermal Dysplasia Meeting in Vienna. Highlights included results from recent animal studies that demonstrated the effectiveness of EDI200. **Click here** to learn more.

We are looking forward to the advancements that 2011 may bring, and we will keep you informed as we move toward our first clinical trial for EDI200.

Thank you for your continued support and membership in the XLHED Network.

Sincerely,
Edimer Pharmaceuticals

